Pricing of HPV vaccines in European tender-based settings

Qendri, Venetia; Bogaards, Johannes A.; Berkhof, Johannes

doi:10.1007/s10198-018-0996-9

Cited by 21 publications

(37 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Qendri et al has retrieved the procurement notices and awards from 15 European countries, and found that prices of first-generation HPV vaccines decreased from USD 122.2 (EUR 101.8) in 2007 to USD 34.1 (EUR 28.4) in 2017, whereas the average dose price of the nine-valent vaccine in 2016–2017 was USD 58.9 (EUR 49.1). The unit prices were, respectively, in the range of USD 9.0 (EUR 7.5) and USD 41.3 (EUR 34.4) higher for the four-valent and nine-valent vaccines than for the two-valent vaccine [ 18 ].…”

Section: Resultsmentioning

confidence: 99%

“…On an annual basis, the contract volume was associated with a decrease in the per-dose price of USD 13.21 (EUR 11.0) per 100,000 doses per year. Additionally, regional level procurement of vaccines resulted in higher unit prices, USD 10.68 (EUR 8.9) per dose when compared to the procurement at the national level [ 18 ]. Similarly, offers received from both manufacturers lowered the unit price of vaccine by USD 5.40 (EUR 4.5) compared to procurement that received only one offer [ 18 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Vaccine Prices: A Systematic Review of Literature

et al. 2020

View full text Add to dashboard Cite

Vaccines are among the most vital interventions to control and reduce the morbidity and mortality worldwide. In accessing vaccines, pricing is usually the single most important deciding element. However, there is a scarcity of the literature on the vaccines pricing. The current study aims to review vaccine prices from the published literature and to evaluate factors that impact the pricing of vaccines. The literature (from 2015–2020) was reviewed to identify the original research articles. Systematic searches were conducted across the five databases including, Google Scholar, PubMed, Science Direct, Scopus and Springer Link. Literature search yielded 23,626 articles, of which 7351 were screened and 7310 articles were excluded based on title and abstracts relevance. The 41 studies were selected for full text review and 4 studies were found to meet the inclusion criteria. The included studies discussed vaccine prices for childhood vaccines, for Human Papilloma Virus (HPV) in US, China and in Europe. One study detailed the various scenarios of the HPV vaccines pricing. It was found that recently introduced vaccines have higher prices owing to the involvement of technology and research for their manufacture. However, prices tended to decrease over some maturation in price and by the involvement of Global Alliance for Vaccine Initiative (GAVI) and other allies. The prices of vaccines in China were much lower than the other high-income countries and the prices offered through United Nations Children’s Fund (UNICEF), mainly due to the large scale of demand in China. The affordable prices of vaccines were related to delicate procedures involving multiple stakeholders and a shorter duration of contract. This review systematically evaluated the literature and identified key factors that could impact vaccines pricing. The prices were higher for the newly introduced vaccines into the market. However, with the price maturation, there was a decline in the pricing and affordable prices could be achieved through tender pricing and involvement of GAVI and other allies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Vaccine Prices: A Systematic Review of Literature

et al. 2020

View full text Add to dashboard Cite

show abstract

“…and are heavily examined against many diverse pathogens including influenza A, Norovirus, Chikungunya virus, cytomegalovirus, rotavirus and Group A Streptococcus, to name a few [ 8 , [12] , [13] , [14] , [15] ]. However, the production and purification of existing commercial VLPs is challenging, making them comparatively expensive vaccines [ 11 , 16 , 17 ]. VLPs can be expressed in a variety of eukaryotic and prokaryotic systems, ranging from mammalian and insect cells to microbial, yeast and plant based systems [18] .…”

Section: Introductionmentioning

confidence: 99%

Comparative evaluation of integrated purification pathways for bacterial modular polyomavirus major capsid protein VP1 to produce virus-like particles using high throughput process technologies

Gerstweiler

Billakanti²,

et al. 2021

Journal of Chromatography A

View full text Add to dashboard Cite

“…When considering both-sex vaccination evaluations, it should be noted that the context is usually female-only vaccination as the comparator because most countries introduced female-only vaccination first; cost-effectiveness will thus be dependent on the vaccine coverage in girls and vaccine price. Recent evidence shows that list prices are rarely paid in national or regional vaccination programs [33]. The actual price paid for vaccines at a regional or country level is often an outcome of confidential tender negotiations and may not be available to use in an analysis; in this situation it is recommended that threshold analysis be performed to determine the maximum price that should be paid.…”

Section: Domain 1 Reporting Modelled Evaluations Of Hpv Vaccination mentioning

confidence: 99%

“…Very little work modelling vaccination of older people has been performed thus far. However, the original evaluations of female HPV vaccination in relation to the optimal age of catch-up are very relevant to evaluations of untargeted vaccination to older ages [33]. Some of the original catch-up vaccination modelling literature was difficult to interpret because a wide age range of vaccination was modelled.…”

Section: Domain 2 - Additional Issues In Reporting Vaccination In Oldmentioning

confidence: 99%

HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control

Canfell

Kim²,

Kulasingam

et al. 2019

Papillomavirus Research

Self Cite

View full text Add to dashboard Cite

Intense research activity in HPV modelling over this decade has prompted the development of additional guidelines to those for general modelling. A specific framework is required to address different policy questions and unique complexities of HPV modelling. HPV-FRAME is an initiative to develop a consensus statement and quality-based framework for epidemiologic and economic HPV models. Its development involved an established process. Reporting standards have been structured according to seven domains reflecting distinct policy questions in HPV and cancer prevention and categorised by relevance to a population or evaluation. Population-relevant domains are: 1) HPV vaccination in pre-adolescent and young adolescent individuals; 2) HPV vaccination in older individuals; 3) targeted vaccination in men who have sex with men; 4) considerations for individuals living with HIV and 5) considerations for low- and middle-income countries. Additional considerations applicable to specific evaluations are: 6) cervical screening or integrated cervical screening and HPV vaccination approaches and 7) alternative vaccine types and alternative dosing schedules. HPV-FRAME aims to promote the development of models in accordance with an explicit framework, to better enable target audiences to understand a model's strength and weaknesses in relation to a specific policy question and ultimately improve the model's contribution to informed decision-making.

show abstract

Pricing of HPV vaccines in European tender-based settings

Cited by 21 publications

References 40 publications

Vaccine Prices: A Systematic Review of Literature

Vaccine Prices: A Systematic Review of Literature

Comparative evaluation of integrated purification pathways for bacterial modular polyomavirus major capsid protein VP1 to produce virus-like particles using high throughput process technologies

HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control

Contact Info

Product

Resources

About